FDA receives additional marketing application for Janssen ZYTIGA
Janssen-Cilag International NV has also sent a type II variation to the European Medicines Agency (EMA) for approval. The two applications are intended to increase the uses of
US-based gene therapy biotech Seawolf Therapeutics and Sanofi have signed a multi-target research partnership and exclusive licensing deal worth up to $1.2bn to develop treatments for bleeding disorders and other undisclosed indications.
Under the agreement Clarity’s PET based companion diagnostics and radio-immunotherapeutics development program will receive cGMP chemistry manufacturing,scale up and aseptic fill/finish services and analytical support from Dalton Pharma.